Sneha Talankar

  • Laboratory Centrifuge Market Overview With Detailed Discussion Of Key Vendor

    The players in the worldwide laboratory centrifuge market are concentrating on item launch with a technological distinction. The focused scene is broadly divided because of solid emergence of a few players. Organizations are likewise foreseen that they would concentrate on clinical trials, joint ventures, research and development, mergers, and acquisitions to stay in ahead of the opposition. A portion of the main players in the worldwide laboratory centrifuge market are Thermo Fisher Scientific Inc., Andreas Hettich GmbH & Co.KG, Hitachi Koki Co., Ltd. (Subsidiary of Hitachi, Ltd.), Sigma Laborzentrifugen GmbH, Cole-Parmer Instrument Company, LLC.( Subsidiary of GTCR firm), Sartorius AG, Eppendorf Group, QIAGEN N.V., Beckman Coulter, Inc. (Subsidiary of Danaher Corporation), and KUBOTA Corporation.

    Download Sample Copy of Laboratory Centrifuge Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26744

    As per the report by Transparency Market Research (TMR), the worldwide laboratory centrifuge market was evaluated to be around worth US$ 1,400.00 mn in year 2016. This value is foreseen to reach worth US$ 1,833.29 mn before the finish of year 2025. Amid the estimated period from 2017 to 2025, the worldwide market is evaluated to surge at an unfaltering CAGR of 3.1%. Regarding capacity, the micro-centrifuges fragment is assessed to stand ahead of the worldwide market because of their broad utilization in different processes in diagnosis. On the basis of geographical region, North America was assessed to be commanding the worldwide laboratory centrifuge market in year 2016.

    Development in Life Science Sector to Support the Surge in Laboratory Centrifuge Market

    The worldwide laboratory centrifuge market is foreseen to be driven by quick development of life science industry worldwide and rising interest from social insurance offices. The extension and union of symptomatic labs in the created areas, for example, North America and Europe is probably going to fuel the interest for laboratory centrifuge amid the conjecture time frame. Late headway in the rotor outline, rotor material, and rotor trade innovation makes the centrifuge operation more straightforward and safe.

    Read Press Release of Laboratory Centrifuge Market : https://www.transparencymarketresearch.com/pressrelease/laboratory-centrifuge-market.htm

    Additionally, improved wellbeing highlights in centrifuges to keep the mechanical harms would add to the markets development. The interest for robotized laboratory centrifuge is along these lines foreseen to be enormously determined by the clinical and indicative labs where substantial number of tests are handled inside brief span of time. In addition the expanded uses of genomics and proteomics in the fields of medication revelation, directed treatment, in the pre-birth analysis and treatment of hereditary ailment and so on factors are probably going to drive the request or laboratory centrifuge amid the figure time frame.

    Slow Upgrades in Diagnostic Labs to Hamper the Growth in Global Market

    Expanding venture by the main global healthcare facilities and diagnosis lab specialist organizations would fuel the district’s development. The high emergence of irresistible sicknesses, and other incessant ailments prompted increment in number of natural example preparing in profoundly populated nations like in India and China. These components are probably going to drive the interest for laboratory centrifuge in not so distant future. Laboratory centrifuges have expansive utilizations of in the fields of atomic science, blood donation centers, biopharmaceutical industry for new particle advancement, in social insurance offices for determination of irresistible illness and ceaseless ailment, and in clinical and preclinical labs for examine reason. In this manner, the developing number of utilizations of laboratory centrifuges is required to fuel market development soon.

    Then again, the worldwide laboratory centrifuge market additionally faces some intense difficulties. By and by, the market is being obstructed by the moderate pace of redesigns in analytic labs of creating economies. Absence of money related help, poor specialized learning, and inadequacy of gifted work have forestalled laboratory updates in rising economies. Moreover, immaterial emergence of research facilities in the regional parts of the world are additionally liable to hamper the worldwide market.


  • Ultrasonic Scalpels Market Views Sought On New Approach

    The worldwide ultrasonic scalpels market is guessed to be set apart by the nearness of best level organizations, for example, BOWA-electronic GmbH and Co. Misonix, Inc., Ethicon, Inc., Söring GmbH, KG, and Olympus Corporation. With respect to set up players, the report could fill in as a complete rule to enhance their offers in the market. Leading organizations working in the market were painstakingly profiled by the examination experts, contemplating different viewpoints, for example, upcoming advancements, item portfolio, critical business systems, SWOT investigation, and friends and monetary review.

    According to a research report by Transparency Market Research (TMR), the worldwide ultrasonic scalpels market is predicted to ascend at a strong CAGR of 7.9% within the gauge time frame from 2017 to 2025 to accomplish a evaluation worth of US$ 4.6 bn by the last figure yea. In year 2016, the market was evaluated worth US$ 2.3 bn. As per the technique, the overall operation market was expected to account for a bigger share in the coming years. By area, North America region is likely to take a ruling place in the market with an evaluated worth of a US$ 1.9 bn by year 2025.

    Download Sample Copy of Ultrasonic Scalpels Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=36530

    The elements that drive the development of the worldwide ultrasonic surgical blade market are expanding interest for surgical systems, for example, lung biopsy, thyroidectomy, and tonsillectomy; ascend in the commonness of perpetual sickness that requires surgical mediations, and mechanical headways in medicinal instruments. In any case, stringent government controls and high expenses of surgical techniques frame the real limitations for the market development. Furthermore, persistent advancement of novel gadgets by key players is expected to give lucrative development openings.

    Awareness about Minimally Invasive Procedures to Boost the Market Demand

    The global ultrasonic scalpels market is forecasted to accomplish development because of the rising check of minimally obtrusive surgical systems played out every year. There is a surge selection of ultrasonic scalpels in the current years as a result of the rise of new gadgets in the business, for example, SONICBEAT that was furnished with cutting edge innovation. Moreover, the expanding utilizations of ultrasonic scalpels in a huge extent of surgical techniques, for example, cerebrum operation have been anticipated to decide the level for a critical development in the market.

    Read Press Release of Ultrasonic Scalpels Market : https://www.transparencymarketresearch.com/pressrelease/ultrasonic-scalpels-market.htm

    The progression of ultrasonic scalpels utilizing the abilities of ultrasound innovation has brought about the coming of magnetic resonance imaging (MRI) – guided centered ultrasound and other latest systems for treating disease and carrying out other surgical techniques. Sellers working in the universal ultrasonic scalpels market have been anticipated to confront challenges because of the costly cost of items. Also, extortionate costs caused for leading surgical techniques and strict government directions could hamper the interest for ultrasonic scalpels.

    Rise in Number of Patients to Propel Ultrasonic Scalpels Market

    By and by, the consistent improvement of novel ideas and items has been visualized to make sufficient of chances in the worldwide ultrasonic scalpels market. Major players, for example, Olympus Corporation have been taking to the selection of ergonomic and latest outlines to update their items for encouraging specialists with more proficiency when performing operational strategies. The pattern of offering innovatively propelled items and presenting more advancements in the market could be a result of well-known brands inclination among medicinal services suppliers.

    The high development of overall surgical techniques because of the rising rate of constant conditions and a huge patient pool, for example, hernia and stoutness have been anticipated to enable the universal ultrasonic scalpels to market to welcome more development scope in the coming years.


  • Bioactive Wound Management Market Is Thriving Worldwide Made Available By Top Research Firm

    With the presence of a number of large-, medium-, and small-scale vendors, the global bioactive wound management market demonstrates a competitive and fragmented business landscape, finds a new research study by Transparency Market Research (TMR). The leading players in this market are taking up creative strategies and are introducing novel products constantly in order to ensure product differentiation to gain an edge over their competitors.

    Going forward, the shifting focus of these vendors towards expansion in various economies, together with the strong presence of local players in several countries, is projected to intensify the competition within this market in the years to come, reports the study.

    Download Sample Copy of Bioactive Wound Management Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33419

    According to the research report, the opportunity offered in this market will reach US$1.1 bn by 2017 end. Progressing at a CAGR of 11.90% during the period from 2017 to 2022, the market is expected to rise to US$2.05 bn by the end of the period of the forecast.

    Increasing Geriatric Population to Fuel Demand for Bioactive Wound Management Solutions

    “On account of the significant rise in the global geriatric population and the subsequent prevalence of diabetes, leading to an increase in a number of wound-caused diseases, is the key factor that is propelling the worldwide market for bioactive wound management,” says a TMR analyst. The increasing prevalence of various chronic diseases, such as diabetes, cardiovascular and peripheral vascular disorder, and several other debilitating diseases, has resulted in an alarming surge in cases of chronic wounds, propelling the adoption of advanced wound care products and, consequently, stimulating this market. Apart from this, the augmenting awareness regarding healthcare among people across the world, upswing in the preference for tissue replacement therapy, and the rising demand for bioactive material are also driving the growth of this market, noticeably.

    Read Press Release of Bioactive Wound Management Market : https://www.transparencymarketresearch.com/pressrelease/bioactive-wound-management-market.htm

    On the other hand, the high cost incurred in the deployment of bioactive wound management solutions are projected to limit their adoption in the near future, hampering the market. However, the increasing demand of technologically advanced and highly effective wound care products among medical professionals is expected to create the need for efficient management, reflecting greatly on this market over the next few years.

    Advanced Healthcare Infrastructure to Help North America Maintain Dominance

    The research report also presents a comprehensive study of the global market for bioactive wound management market. As per the study, North America, Asia Pacific excluding Japan (APEJ), Europe, the Middle East and Africa (MEA), Latin America, and Japan are the the main regional markets for bioactive wound management solutions and services across the world. Among these, North America is the current market leader. Rising at a CAGR of 12.80%, the North America market for bioactive wound management is likely to maintain its dominance on the global market over the period of the forecast. The presence of a highly advanced and sophisticated healthcare infrastructure is expected to propel this regional market in the near future, states the research report.


  • Stretch Marks Treatment Market Industry Technology, Growth Prospects And Trends Analyzed Till 2025

    Transparency Market Research (TMR) anticipates that the key players in the stretch mark treatment market are looking to expand their global reach and customer base. In order to achieve this, the key players are entering into merger and acquisitions. Additionally, the key players are focusing on the product innovation and development of effective solutions. Some of the key players in the global stretch mark treatment market are Clarins Group, Laboratoires Expanscience, Merz North America, Inc., Syneron Medical Ltd., Cynosure, Inc., E.T. Browne Drug Co., Inc. Some of the other prominent players in the market include Basq Skincare, Union-Swiss (Pty) Ltd., Ellipse A/S, Helix BioMedix, Inc., The Boppy Company LLC, Weleda AG, Mama Mio US, Inc., Dermaclara, Inc., and Centre Light Solutions, LLC.

    According to the report by TMR, the stretch marks treatment market is estimated to grab a value of US$1.99 bn by 2025-end. The market is estimated to exhibit a healthy CAGR of 5.40% from 2017 to 2025.

    Download Sample Copy of Stretch Marks Treatment Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33128

    Based on the treatment, the topical products segment dominated the global stretch marks treatment market and is estimated to remain the key region over the forecast period. This is primarily attributable to the comparatively cheaper price and easy availability through the wide-ranging distribution channel. Regionally, the market in North America dominated the global stretch marks treatment market and is estimated to remain dominant in the coming years. The market in the region is estimated to expand at CAGR of 5.2% during the forecast period from 2017 to 2025 and grab a value of US$676.3 mn by 2025. Europe is trailing North America in terms of market share. The market in the Europe region is predicted to reach a valuation of US$531.7 mn by 2025. The market is predicted to exhibit a growth rate of 5.6% in the coming years.

    Read Press Release of Stretch Marks Treatment Market : https://www.transparencymarketresearch.com/pressrelease/stretch-marks-treatment-market.htm

    Rising Concerns over Aesthetics Propels Market Growth

    Rising incidences of the stretch marks are catalyzing growth of the global stretch marks treatment market. Additionally, the growing prevalence of obesity due to rising fast food and changing eating habits globally and especially in the developing countries is driving growth of the global stretch marks treatment market. Furthermore, the rising disposable income of people due to urbanization and industrialization globally is changing people’s lifestyle. This has led to an increase in concerns over personal aesthetics and fuel the stretch marks treatment market. Additionally, due to rising penetration of Internet has emerged the social media and easy access to the information on the web. This factor has resulted in awareness about the availability of effective treatments. These factors are favoring growth of the global stretch marks treatment market.

    Risks of Possible Side Effects Restrains Market Growth

    Furthermore, booming e-commerce platforms globally are making the effective treatments available globally, which is benefitting growth of the global stretch marks treatment market. However, high costs of some of the treatments in some cost-sensitive areas are restraining growth of the global stretch marks treatment market. Additionally, fear of possible side effects on skin and other parts such as rashes and itchiness is restraining growth of the global stretch marks treatment market.

    Nonetheless, the availability of a vast range of products serving different needs coupled with continuous research and development activities by keen players is estimated to offer the most lucrative opportunities for growth in the coming years. Moreover, rising attention toward lowering side effects by key players is estimated to offer lucrative growth opportunities for growth in the coming years.

    This information is encompassed in the report by TMR, titled, “Stretch Marks Treatment Market (Treatment – Topical Products (Creams, Oils and Serum, and Lotions), Lasers (Fractional Lasers and Pulse-Dye Lasers), and Microdermabrasion; End-user – Hospitals, Clinics, Specialty Dermatology Centers, and Home-use) – Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 – 2025.”

    Tags

  • Endoscopy Equipment Market Opportunity Assessment By Top Players Forecast 2017 to 2025

    The global endoscopy equipment market is estimated to witness notable growth in the coming years as Transparency Market Research reports. This is due to the increasing number of gastrointestinal diseases as well as cancer. The competitive landscape of the global endoscopy equipment market is seen to be fragmented due to the presence of a large number of players. Major players are putting more focus on the development of new products and their product launching in order to stay in the market and maintain a dominant place.

    Some of the prominent players of the global endoscopy equipment market are Fujifilm Holdings Corporation, Stryker Corporation, Karl Storz GmbH & Co., Smith & Nephew Plc, Karl Storz GmbH & Co., Boston Scientific Corporation, and Arthrex Inc. Major vendors are making efforts to develop new products and accelerate the overall growth of the market during the forecast period. Players are also investing more funds into research and development in order to produce better and unique results so as to improve their brand quality and give tough competition to the others.

    Download Sample Copy of Digital Therapeutic Devices Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33032

    As per the TMR reports, the global endoscopy equipment market is prognosticated to reach a valuation of US$33.5 bn by 2022. The market is presumed to exhibit a promising CAGR of 4.0% within the forecast period of 2017 to 2022. As per the classification by application, the endoscopy equipment market is seen to be dominated by the gastroenterology segment owing to the increase in popularity of gastric problems all around the globe.

    As per the geographical segmentation, the market is projected to be dominated by North America with an expected rise of revenue from US$9.9 bn in 2017 to US$12.3 bn by the end of 2022.

    Read Press Release of Digital Therapeutic Devices Market : https://www.transparencymarketresearch.com/pressrelease/endoscopy-equipment-market.htm

    Increasing Number of Gastroenterological Diseases to Boost Market Growth

    The surge in the use of endoscopic equipment for diagnosis of all kinds of gastroenterological disorders is also expected to boost the market at a global level. Another factor expected to boost the global market for endoscopy equipment is the rising investments in healthcare and medical sector for their enhancement is among the key driver to boost the overall market growth. Both the government and non-government agencies are putting efforts to set up better healthcare infrastructures in order to suffice to the medical needs of people.

    Developing countries like that of New Zealand, Australia, India, China, and Japan are also presumed to increase the revenue generation of the endoscopy equipment market during the forecast period by creating better infrastructure and medical facilities in terms of treatment. The emergence and popularity of ultra-modern healthcare facilities are also creating lucrative opportunities for the overall market for endoscopy equipment.

    High Cost of Treatment of Endoscopy to Cause Hindrance to Market Growth

    One factor that may act as a hindrance to the overall growth of the market is the high treatment cost of gastroenterology and their medication as well. The high cost of treatment may make customers to think twice before opting for such treatment. Apart from that, the emerging market for ayurvedic medicines and their guaranteed no side-effect propaganda may divert patients from opting for endoscopic treatment and instead acquire natural remedies in order to cure themselves. Due to this shift, the market for endoscopy equipment may also face loss in the years to come.

    The information presented above is based on the findings of a research report published by Transparency Market Research (TMR), titled, “Endoscopy Equipment Market (Product Type – Endoscopes, Operative Devices, Visualization Systems; Application – Gastroenterology, Respiratory Tract, Orthopedics, Gynecology and Urology, Pulmonology, Otorhinolaryngology; End Use – Hospitals, Diagnostic Centers, Specialized Clinics) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2022.”


  • Contraceptives Market Is Thriving Worldwide By 2025

    The demand within the global market for contraceptives has been rising on account of the growing incidence of sexually transmitted diseases, finds Transparency Market Research (TMR). The competitive dynamics of the global market for contraceptives have drastically changed over the past decade. The key players have resorted to informative marketing practices in order to create a regular consumer base. There is a high possibility of new business practices coming to the fore of the global contraceptives market. Moreover, the presence of established vendors in the global market for contraceptives is a key consideration for newbie vendors as well.

    It is expected that strategic alliances amongst large, medium, and small-scale vendors would be a common trend in the global contraceptives years to come. This will help the larger vendors in accessing the regional markets, while the smaller vendors could learn from the strategies of the established vendors. Furthermore, mergers and acquisitions are also projected to be a key trend in the global contraceptives market in the years to come. It is safe to prognosticate that new and more effective forms of contraceptives would be introduced by the vendors in the years to come. Some of the key vendors in the global contraceptives market are Allergan plc, Mankind Pharma, Janssen Pharmaceutical Company, Mithra Pharmaceuticals, HLL Lifecare Limited, and Cipla Inc.

    Download Sample Copy of Contraceptives Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=344

    Transparency Market Research (TMR) finds that the global contraceptives market would expand at a healthy CAGR of 6.10% over the period between 2017 and 2025. The cumulative value of the global contraceptives market would reach US$ 37,242.7 mn by 2025-end, rising up from a value of US$ 22,050 mn in 2016. On the basis of product, the demand for oral contraceptives is on a rise in recent times. Based on geography, the market for contraceptive in North America is expanding at a stellar pace due to growing awareness about STDs in the US and Canada.
    Awareness Campaigns about STDs to Propel Demand

    The rising incidence of sexually transmitted diseases has led national and international bodies to launch awareness campaigns. Several offline and online platforms have been leveraged to educate people about the need for using contraceptives. Hence, the demand within the global market for contraceptives is projected to escalate to new heights in the years to come. Furthermore, the availability of contraceptives such as condoms, vaginal rings, and pills across pharmacies has also aided market growth. Besides this, the presence of key vendors for producing various types of contraceptives has also aided market growth.

    Read Press Release of Contraceptives Market : https://www.transparencymarketresearch.com/pressrelease/contraceptives-market.htm

    Easy Availability of Contraceptive Devices to Propel Demand

    The global market for contraceptives has expanded at a starry pace in recent times. The availability of several nascent contraceptives such as contraceptive sponges, vaginal rings, female condoms, and diaphragms has created commendable opportunities for growth within the global market. Furthermore, contraceptives are now available across a number of selling points including pharmacies, online platforms, clinics, and hospitals. This factor has also emerged as a crucial driver of demand within the global contraceptives market. Promotion of contraceptive-use across schools and colleges has also led to the growth of the global market.


  • Infection Prevention Devices Market Size will Observe Substantial Growth by 2027

    Global Injectable Cement Market: Overview

    Injectable cement market is gaining major momentum in coming years owing to to rising geriatric population across the globe. These biocompatible materials can be used in sugeries of bone defect in maxillofacial instances. The rising cases of such surgeries are another factor that is driving the growth of global injectable cement market. Also, use of polymethylmethacrylate and calcium is yet another factor that promotes the growth of the market. Moreover, various factors such as compatible viscosity, porosity, radiopacifiers, and easy sterilization processes are some more factors that are fueling the growth of global injectable cement market.

    A Recent TMR report provides a complete study of global injectable cement marketmarket. It covers various aspects that are influencing the growth of the market. The report also provides an in-depth study of various facets such as notable developments, key players, regional analysis, and multiple opportunities that global injectable cement market has to offer to various businesses.

    Need an Overview of the Report on Injectable Cement Market? Ask for the Brochure Injectable Cement Market

    Global Injectable Cement Market: Notable Developments

    The global injectable cement marketmarket is majorly fragmented. The market is dominated by some of the major players across the globe. In order to stay ahead of the competition, the players of global injectable cement marketare adopting strategies such as mergers, partnerships, and collaborations. Also, they are focusing on various research and development activities in order to launch new products. This helps businesses to retain their customers in a highly competitive market. Some players are also acquiring various small and medium scale businesses in order to enhance their production capacity and gain a much required competitive edge over the competitors.

    • In January, 2018, Heraeus Medical made bone cement direct available in the United States. This move provides an opportunity for the surgeons in US to offer better service to the patients.

    Some of the prominent players of global injectable cement market are Stryker, Johnson and Johnson, Heraeus Medical, Smith and Nephew, Braun Melsungen AG, Medtronic, Alphatec Spine, DJO Global, and Tecres.

    Global Injectable Cement Market: Key Drivers

    Growth of global injectable market is majorly driven by the technological advancements in healthcare sector. Also, the use of injectable cement market in surgeries for osteoporosis and trauma is also influencing the growth of global injectable cement market. Moreover, rise in geriatric population is various countries across the globe is contributing the growth of global injectable cement market in coming years. Furthermore, the rise in cases of major accidents across the globe is one of the major factors that accounts for the growth of global injectable cement market.

    Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “Injectable Cement Market” here

    However, higher cost of various bone related surgeries is expected to hamper the growth of global injectable cement market in forecast period of 2019 to 2027. Nevertheless, growing disposable income and flexible insurance cover in various countries across the globe is expected to support the global injectable cement market to sustain its growth in the forecast period. Moreover, growing number of hospitals and clinics in various parts of the country are also aiding the growth of global injectable cement market in the forecast period of 2019 to 2027.

    Global Injectable Cement Market: Regional Analysis

    The largest consumer of injectable cement market is Europe by volume as well as revenue generation. Demand from Europe is followed by Asia Pacific and North America. Asia Pacific market is expected to exhibit the swiftest growth rate owing to the increased applicability and demand from end use industries. The fact that the manufacturing hub of the world is located in this region also drives the growth in Asia Pacific. India, China, Russia, and Brazil are expected to show persistent demand in the foreseeable future.

    The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

    The study is a source of reliable data on:

    • Market segments and sub-segments
    • Market trends and dynamics
    • Supply and demand
    • Market size
    • Current trends/opportunities/challenges
    • Competitive landscape
    • Technological breakthroughs
    • Value chain and stakeholder analysis

  • Cell Separation Technology Market Value Projected to Expand by 2027

    Transparency Market Research (TMR) has published a new report on the global cell separation technology market for the forecast period of 2019–2027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

    Overview

    Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

    Request a Sample of Red Biotechnology Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

    Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such as stem cell research and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

    North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region. 

    Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

    Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach 73%, and in developing counties, 70% deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market. 

    Increase in Geriatric Population Boosting the Demand for Surgeries

    The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimer’s, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

    According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion by 2100. 

    Read Press Release of Cell Separation Technology Market: https://www.transparencymarketresearch.com/pressrelease/cell-separation-technologies.htm

    Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

    Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development of microfluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

    Stem Cell Research to Account for a Prominent Share

    Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

    Biotechnology & Pharmaceuticals Companies to Dominate the Market

    The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

    As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration (CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

    Global Cell Separation Technology Market: Prominent Regions

    North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

    In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

    The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

    Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

    The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.


  • Red Biotechnology Market is Projected to Expand at a CAGR of 6% From 2019 to 2027

    Red Biotechnology Market: Competitors’ Concentration on Cancer Therapeutics Research to Underpin Growth

    Ever since the era of biotechnology began, with the development of recombinant DNA (rDNA) techniques, countless experiments and research regarding the implication of biotechnology to boost health continue to spawn. The advancement of biotechnology has opened new doors to designing novel therapeutic drugs for sophisticatedly fighting diseases.

    Rapid advancements in stem cell research emphasize using a patient’s own cells to design highly personalized therapeutic alternatives. Similarly, genetic engineering technology encompasses editing the genetic composition of patients to encounter specific points of interest. Several measures are being taken to explore and incorporate biotechnology into the creation of personalized medical care. The application of biotechnology towards personalized medical treatments is likely to open several opportunities for red biotechnology market competitors. Although red biotechnology sustains on an upward growth trajectory in wake of its consist contribution in bettering healthcare, it is imperiled to potential setbacks that cannot be denied. The influence of regional governance on the pricing of medication brings along an undermining aspect, as growing innovations need to be remunerated.

    The new study by TMR reveals key insights into the red biotechnology landscape, allowing report audiences to gain a holistic market overview. According to this TMR study, sales revenues from the red biotechnology market valued at US$ 314.2 billion in 2018. The increasing prevalence of chronic diseases, rapid expansion of the biopharmaceutical industry, and increased global expenditure on the healthcare industry are likely to uphold the growth of the red biotechnology market. Moreover, the growing awareness of chronic disease treatment and robust pipeline of new therapeutic molecules are expected to drive the global red biotechnology market.

    Download Brochure Copy of Red Biotechnology Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2063

    Notable Trends Shaping the Future of the Red Biotechnology Market

    AI Ushers in the New Era of Biotechnology Research

    The transforming utilization of artificial intelligence across a wide array of applications has not been unnoticed. Ahead of this, its use has gradually commenced revolutionizing research activities in the field of biotechnology, as it dramatically minimizes the cost and time involved in the development of life-saving drugs. Companies within the biotechnology space have gained a competitive edge with the implications of cloud-based technology and AI, and increased focus on R&D.

    Significant Investments in the Healthcare Space

    There is a continuously growing buoyancy for supporting industries in the biotech sector, including health service companies. Healthcare start-ups are shining brightly for investors, particularly in areas such as biotechnology. The healthcare industry, as a whole, has cited that dollars of investments and higher valuations are likely to stay consistent over the foreseeable future, giving an edge to research activities for biopharmaceutical production.

    Strategic Collaborations Lay the Grounds for Success

    Red biotechnology market players are relying on strategic mergers and acquisitions to strengthen their position in the market. As enhanced therapeutics play a major role in global disease mitigation, red biotechnology market players are emphasizing on strategic collaborations to enhance their level of expertise while bringing in innovative products. With collaboration agreements, red biotechnology market players are likely to gain major support for biopharmaceutical production, which is picking pace rapidly.

    Read Press Release of Red Biotechnology Market: https://www.transparencymarketresearch.com/pressrelease/red-biotechnology-market.htm

    Growing Demand for Therapeutics to Stir New Possibilities

    The growing rate of chronic diseases is compelling researchers to develop advanced drugs and therapeutics that are capable of battling chronic and progressive diseases. On account of continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are gaining significant traction, thereby boosting developments in the red biotechnology market.

    Key Success Strategies for Red Biotechnology Competitors

    Strengthen Partnership and Distribution Agreements in Developing Countries

    Global red biotechnology market players are emphasizing on developing countries, particularly in the Asia Pacific region. With major initiatives taken in response to the growing drug and biologics demand, and growing patient population in this region, global market players concentrate on strengthening distribution and partnership agreements in developing countries to leverage major demand for biopharmaceuticals and biosimilars.

    Looking for exclusive market insights from business experts? Request a Custom Report Red Biotechnology Market

    Expand Global Oncology Portfolio

    Growing incidences of cancer across the globe have spawn major developments in cancer therapeutics, resulting in increasing investments in cancer research and drug development. Red biotechnology market competitors have recognized the importance of cancer therapeutics, directing major focus towards oncology portfolio expansion.

    Greater Investment in R&D to Develop Novel Biopharmaceuticals

    Biopharmaceuticals production continues to be the most sought-after application of red biotechnology on account of the fast-growing demand for these drugs that target disease pathways, and provide superior efficacy and safety. Their ability to treat previously untreatable diseases have made biologics widely accepted among end users, driving the demand for hefty investment in biopharmaceutical R&D.

    Boost Market Presence in the U.S.

    There is a major concentration of entrepreneurialism and research in U.S. biotechnology companies, with a biotechnology cluster based in the country. Higher rate of acceptance of new biopharmaceutical drugs, coupled with massive product launches in North America, is attributed to the dominance of the region, wherein, the U.S. is likely to thrive as a leader in the biotechnology space. A large number of mature biotechnology companies and pharmaceutical manufacturers located in the U.S. are attracting red biotechnology market contributors in a bid to expand their presence in the country.

    Innovative Product Development and Clinical Trials

    Companies operating in the red biotechnology market continue to engage in the development of innovative products and invest in associated clinical trials to gain regulatory backing. As R&D efforts for producing advanced disease therapeutics continues to flourish, red biotechnology innovations remain a vital profit-gaining strategy for competitors.

    Competitive Assessment

    Leading players in global red biotechnology market, including

    • F. Hoffmann-La Roche
    • Amgen Inc.
    • Gilead Sciences Inc.
    • CSL
    • Pfizer Inc.

    accounted for nearly half of the market share in 2018. Expansion strategies such as business acquisitions remain a vital tactic adopted by competitors in the red biotechnology market. Companies are entering into strategic collaborations with other biotechnology firms located in lucrative geographies, in a bid to expand their consumer base. Apart from this, innovative product launches allow red biotechnology market players to strengthen their market position, with focus centered on greater R&D activities. Considering the global inclination towards biosimilars that meet the consumer requirements for both, efficacy and cost-effectiveness, notable developments related to biosimilars remain a focal point for competitors.


  • Acute Kidney Injury Treatment Market to Expand at a CAGR of Around 8% During the Forecast Period

    Acute Kidney Injury (AKI) Treatment Market: Number of Candidate Drugs Increasing

    Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth. 

    Evolution of Acute Kidney Injury (AKI) Treatment

    Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

    Identify the key factors that will drive your company’s growth. Request a brochure Acute Kidney Injury Treatment Market

    The Therapeutic Landscape

    Adoption of AKI Biomarkers

    The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

    Ultrasound Technique – A Traditional Break Through

    Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

    Want to know more such detailed insights of Acute Kidney Injury Treatment Market? Request a PDF sample Acute Kidney Injury Treatment Market

    Market Players Collaborating with Research Institutes to Develop Effective Drugs

    Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

    Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

    Expanding operations in future? To get the perfect launch ask for a custom report of Acute Kidney Injury Treatment Market

    Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

    Mergers and Acquisitions: A Key Strategy

    North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

    Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

    Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

    Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.


  • Sirolimus Market is Expected to Demonstrate a CAGR of 1.0% from 2019 to 2027

    Sirolimus: A Multi-action Promising Drug

    Sirolimus could have a promising role in prophylaxis of rejection, treatment of refractory acute rejection, and chronic allograft dysfunction, as substantiated by various studies. Sirolimus is a new potent immunosuppressant whose profile could offer an advantage over other currently used drugs in view of its absence of intrinsic nephrotoxicity and efficacy as good as cyclosporin. Sirolimus could have both, a steroid sparing as well as a cyclosporin sparing effect.

    Sirolimus may have a beneficial role in prophylaxis of rejection as well as treatment of refractory rejection. Sirolimus also has antifungal, antitumor, and anti-smooth muscle proliferative roles. The global sirolimus market was valued at US$ 285.00 Mn in 2018 and is projected to reach US$ 304.08 Mn by 2027, expanding at a CAGR of 1.0% from 2019 to 2027.

    Promising Pipeline Opening New Market Opportunities

    • Increase in incidence of target diseases, rise in the number of lifestyle-related disorders, promising pipeline, surge in health care spending, and improvement in health care infrastructure are the factors anticipated to drive the global sirolimus market.
    • Furthermore, increase in preference for generic drug variants and associated side effects are expected to restrain the Sirolimus market.

    Request A Sample of Sirolimus Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60162

    Global Sirolimus Market: Report Segmentation

    • In terms of application, the global sirolimus market has been categorized into organ transplant rejection, lymphangioleiomyomatosis (LAM), and sirolimus coated balloons & catheter devices.?
    • The organ transplant rejection segment dominated the sirolimus market in 2018 due to rise in the number of organ transplants.
    • Based on distribution channel, the global sirolimus market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.
    • In terms of region, the global sirolimus market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
    • North America accounted for major share of the global sirolimus market in 2018. The market in the region is driven by the presence of key players and high rate of adoption of technologies.
      • Additionally, rise in the number of organ transplants is projected to propel the market in North America.
      • Increase in incidence of target diseases, rise in prevalence of lifestyle-related disorders, promising pipeline, and surge in health care spending & improvement in health care infrastructure is anticipated to boost market growth.

    Request Brochure of Sirolimus Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60162

    Global Sirolimus Market: Competitive Insights

    The global sirolimus market is highly fragmented due to the presence of a large number of players. Major players operating in the market include Pfizer, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Concept Medical, Inc., Stentys SA, Torrent Pharmaceuticals Ltd., Zydus Cadila, and Intas Pharmaceuticals Ltd.

    Increase in trend of mergers & acquisitions and product approvals & launches in developing countries is expected to boost the global sirolimus market during the forecast period. Additionally, acquisitions drive growth in core business. Product approvals enable companies to enhance product portfolio globally.

    The global sirolimus market has been segmented as follows:

    • Global Sirolimus Market, by Application
      • Organ Transplant Rejection
      • Lymphangioleiomyomatosis (LAM)
      • Sirolimus Coated Balloons & Catheter Devices
    • Global Sirolimus Market, by Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies

  • Vaginal Slings Market: Increase in Investment by Leading Market Players and Healthcare Providers

    Transparency Market Research (TMR) has published a new report titled ‘Vaginal Slings Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global vaginal slings market was valued at US$ 1,676.0 Mn in 2017. It is projected to expand at a CAGR of 4.8% from 2018 to 2026. Rising emphasis on minimally invasive procedures, increasing geriatric population, and increasing awareness about the management of urinary incontinence are some factors that are likely to drive the vaginal slings market from 2018 to 2026.

    Rise in demand for minimally invasive surgery/devices to minimize surgical complications and increase in demand for improved product outcomes and efficiency have led to the development of innovative products and technologies in order to address the unmet needs of patients as well as surgeons. Companies have significantly invested in R&D activities to develop new products and technologies, product designs, and materials in order to improve overall product efficiency and outcomes. Moreover, favorable medical reimbursement policies for incontinence treatment devices in developed countries, such as the U.S., Australia, New Zealand, the U.K., and Germany, have enabled most incontinence-affected patients to opt for effective treatment methods with quality products. These reimbursement policies have significantly driven the revenues for leading global players in the international market.

    Request For Customization of Vaginal Slings Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=48513

    The report offers detailed segmentation of the global vaginal slings market based on product type, type of urinary incontinence, end-user, and region. In terms of product, the transobturator tape slings (TOT) segment is anticipated to hold high share due to low bladder injury, less incision, rising prevalence of urinary incontinence, and promising results of sling surgery in management of urinary incontinence.

    Hospitals to account for major share

    The hospitals segment is expected to account for a leading share of the market by the end of 2026. The segment is also likely to expand at a rapid pace during the forecast period. Hospitals are equipped with all the equipment and consumables required for sling surgery. Moreover, availability of skilled professionals and ability to handle several operations simultaneously are estimated to drive the segment during the forecast period.

    Ask for Discount on Report of Vaginal Slings Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=48513

    Market in Asia Pacific to expand at a significant pace

    North America held a major share of the global market, in terms of revenue, and is expected to maintain its position during the forecast period. North America is home to several key market players, such as Boston Scientific Corporation, C. R. Bard, Inc., and Ethicon Inc., who have their headquarters in the U.S., where they generate significant sales. Hence, North America is a leading market for vaginal slings. Moreover, high awareness about latest health care technologies and higher purchasing power are anticipated to boost the vaginal slings market in North America. Favorable reimbursement policies in the region also enable patients to avail the best health care facilities. The vaginal slings market in Asia Pacific is expected to expand at a rapid pace, primarily due to improving health care infrastructure, rising private and public investment in life science research, and technological advancements in countries such as China and India.

    Europe is projected to follow North America, in terms of share of the market, in terms of revenue, during the forecast period. Developed healthcare infrastructure in Europe has helped patients undergoing vaginal slings in covering their expenditure. Most healthcare providers, in countries such as Germany, the U.K., and France, provide full or partial coverage of costs related to treatment, medication, physicians cost, and tests depending on the patient’s insurance plan and income.

    Key players, such as Coloplast, Boston Scientific Corporation, and Ethicon, Inc., to lead the market

    The report also provides profiles of leading players operating in the global vaginal slings market. The major players include Promedon Group, A.M.I. GmbH, Ethicon, Inc. Medtronic plc, ABISS, Betatech Medical, and Caldera Medical.

    Tags

  • Advanced Wound Care Management Market: Increase in Trauma and Accident Cases Across the Globe Drives

    Transparency Market Research (TMR) has published a new report titled, “Advanced Wound Care Management Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global advanced wound care management market was valued at US$ 8.5 Bn in 2016 and is projected to expand at a CAGR of 5.8% from 2018 to 2026. Surge in incidence of chronic wounds and trauma cases is anticipated to boost the demand for advanced wound care management during the forecast period. North America and Europe are projected to dominate the global advanced wound care management market owing to higher rate of adoption and awareness regarding wound care management. Asia Pacific, Latin America, and Middle East & Africa are potential markets for advanced wound care management. The market in Asia Pacific is expected to expand at a CAGR of 6.3% from 2018 to 2026.

    Request For Customization of Advanced Wound Care Management Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16139

    Cost-effective advanced wound care management to treat complex wounds to drive global market

    Increase in trauma and accident cases across the globe drives the advanced wound care management market. According to the World Health Organization (WHO), road accidents account for around 1.25 million deaths across the globe each year. Additionally, the number of patients with chronic wounds is rising rapidly across the world. This is likely to increase the number of surgical procedures; consequently, propelling the global advanced wound care management market.

    Chronic wounds to be highly lucrative segment

    Chronic wounds is an emerging segment of the advanced wound care management market. In the chronic wounds segment, the ulcers sub-segment holds a prominent share. Venous leg ulcers account for 80% of all leg ulcers. Moreover, the chronic wounds segment is likely to hold major share due to high cost of therapy across the globe. As per a paper published by NCBI (National Center for Biotechnology Information), in May 2014, the annual burden of venous leg ulcers in the U.S. is nearly US$ 14.9 Bn, which includes indirect costs (productivity loss) as well. The diabetic foot ulcer sub-segment of the advanced wound care products market is expanding at a significant CAGR.

    Ask for Discount on Report of Advanced Wound Care Management Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16139

    Hospitals & clinics to be notably promising segment

    In terms of end-user, the global advanced wound care management market has been segmented into hospitals & clinics, ambulatory surgical centers (ASCs), home health care, and others. The hospitals & clinics segment held major share of the global market in 2017. Expansion of the segment can be attributed to the availability of multiple service options and devices and tie-ups with health care companies in order to enhance health care product and service offerings. Moreover, hospitals are the preferred choice due to availability of advanced technology and better health care services. The home health care segment is expanding at a high growth rate, especially in developed economies, due to rise in geriatric population and increasing health care infrastructure and support. Moreover, rise in demand for advanced wound care management in home care settings for geriatric patients is projected to drive the segment.

    North America expected to dominate global market

    In terms of region, the global advanced wound care management market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global advanced wound care management market in 2017. The market in North America was valued at US$ 3.2 Bn in 2017 owing to a highly developed health care sector, increase in awareness among health care providers about advanced wound care management, and continuous evolution of wound care management. Advanced wound care management market offers significant growth potential in the region. The advanced wound care management market in Asia Pacific is anticipated to expand at a CAGR of 6.3% during the forecast period due to increase in awareness about advanced wound care products and expansion of the health care sector in countries such as China, Japan, and India. Moreover, technological advancements and increase in rate of adoption of advanced wound care management products are expected to propel the market in the region during the forecast period.

    Smith & Nephew plc, Acelity L.P., Inc. and Mölnlycke Health Care AB anticipated to lead global market

    The global advanced wound care management market is highly fragmented in terms of number of players providing different products. Key players in the global advanced wound care management market include Smith & Nephew plc, Acelity L.P., Inc., Mölnlycke Health Care AB, ConvaTec Inc., B. Braun Melsungen AG, Coloplast A/S, 3M Healthcare, Integra LifeSciences Corporation, Cardinal Health, PAUL HARTMANN AG, BSN Medical, Hollister Incorporated, Organogenesis Inc., and Medline Industries, Inc. Expansion of product portfolio through mergers and acquisitions is a key strategy followed by several global players. In December 2015, Acelity L.P., Inc. announced the acquisition of Spiracur, Inc., expanding its offering in disposable, portable, mechanical NPWT (Negative-pressure wound therapy) technology, and allowing sales and service channels to boost the expansion of the SNaP therapy system to patients and their care teams across the world who need access to NPWT devices.


  • Acute Kidney Injury Treatment Market is Expected to Demonstrate a CAGR of 8%

    Acute Kidney Injury (AKI) Treatment Market: Number of Candidate Drugs Increasing

    Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth. 

    Evolution of Acute Kidney Injury (AKI) Treatment

    Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

    Download Brochure Copy of Acute Kidney Injury Treatment Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67523

    The Therapeutic Landscape

    Adoption of AKI Biomarkers

    The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

    Ultrasound Technique – A Traditional Break Through

    Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

    Read Press Release of Acute Kidney Injury Treatment Market: https://www.transparencymarketresearch.com/pressrelease/acute-kidney-injury-treatment-market.htm

    Market Players Collaborating with Research Institutes to Develop Effective Drugs

    Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

    Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

    Expanding operations in future? To get the perfect launch ask for a custom report of Acute Kidney Injury Treatment Market

    Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

    Mergers and Acquisitions: A Key Strategy

    North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

    Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

    Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

    Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.


  • Sirolimus Market will Exhibit a CAGR of 1.0% from 2019 to 2027

    Sirolimus: A Multi-action Promising Drug

    Sirolimus could have a promising role in prophylaxis of rejection, treatment of refractory acute rejection, and chronic allograft dysfunction, as substantiated by various studies. Sirolimus is a new potent immunosuppressant whose profile could offer an advantage over other currently used drugs in view of its absence of intrinsic nephrotoxicity and efficacy as good as cyclosporin. Sirolimus could have both, a steroid sparing as well as a cyclosporin sparing effect.

    Sirolimus may have a beneficial role in prophylaxis of rejection as well as treatment of refractory rejection. Sirolimus also has antifungal, antitumor, and anti-smooth muscle proliferative roles. The global sirolimus market was valued at US$ 285.00 Mn in 2018 and is projected to reach US$ 304.08 Mn by 2027, expanding at a CAGR of 1.0% from 2019 to 2027.

    Promising Pipeline Opening New Market Opportunities

    • Increase in incidence of target diseases, rise in the number of lifestyle-related disorders, promising pipeline, surge in health care spending, and improvement in health care infrastructure are the factors anticipated to drive the global sirolimus market.
    • Furthermore, increase in preference for generic drug variants and associated side effects are expected to restrain the Sirolimus market.

    Download Brochure Copy of Sirolimus Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=66860

    Global Sirolimus Market: Report Segmentation

    • In terms of application, the global sirolimus market has been categorized into organ transplant rejection, lymphangioleiomyomatosis (LAM), and sirolimus coated balloons & catheter devices.?
    • The organ transplant rejection segment dominated the sirolimus market in 2018 due to rise in the number of organ transplants.
    • Based on distribution channel, the global sirolimus market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.
    • In terms of region, the global sirolimus market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
    • North America accounted for major share of the global sirolimus market in 2018. The market in the region is driven by the presence of key players and high rate of adoption of technologies.
      • Additionally, rise in the number of organ transplants is projected to propel the market in North America.
      • Increase in incidence of target diseases, rise in prevalence of lifestyle-related disorders, promising pipeline, and surge in health care spending & improvement in health care infrastructure is anticipated to boost market growth.

    Read Press Release of Sirolimus Market: https://www.transparencymarketresearch.com/pressrelease/sirolimus-market.htm

    Global Sirolimus Market: Competitive Insights

    The global sirolimus market is highly fragmented due to the presence of a large number of players. Major players operating in the market include Pfizer, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Concept Medical, Inc., Stentys SA, Torrent Pharmaceuticals Ltd., Zydus Cadila, and Intas Pharmaceuticals Ltd.

    Increase in trend of mergers & acquisitions and product approvals & launches in developing countries is expected to boost the global sirolimus market during the forecast period. Additionally, acquisitions drive growth in core business. Product approvals enable companies to enhance product portfolio globally.

    The global sirolimus market has been segmented as follows:

    • Global Sirolimus Market, by Application
      • Organ Transplant Rejection
      • Lymphangioleiomyomatosis (LAM)
      • Sirolimus Coated Balloons & Catheter Devices
    • Global Sirolimus Market, by Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies

  • Urinary Incontinence Treatment Devices Market to Expand at a CAGR of 7.5% from 2019 to 2027

    Transparency Market Research (TMR) has published a new report titled, Urinary Incontinence Treatment Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.According to the report, the global urinary incontinence treatment devices market was valued at US$ 2.21 Bn in 2018 and is projected to expand at a CAGR of 7.5% from 2019 to 2027. High prevalence of urinary incontinence and overactive bladder across the globe and technological advancements such as non-implantable electrical stimulation devices are anticipated to boost the growth of the global market during the forecast period. North America and Europe are expected to dominate the global urinary incontinence treatment devices market from 2019 to 2027. This is attributed to rise in demand for minimally invasive surgery/devices for urinary incontinence treatment, favorable medical reimbursement policies, and rapidly increasing geriatric population. Asia Pacific is likely to account for significant market share by 2027. This is due to large urinary incontinence patient base in highly populated countries such as India and China, large geriatric population in Japan, and rise in adoption of technologically advanced products in Japan, Australia, New Zealand, and South Korea. Rise in adoption of technologically advanced products by key manufacturers such as Medtronic plc, Boston Scientific Corporation, and Cogentix Medical is projected to propel the global urinary incontinence treatment devices market. The market in Europe is anticipated to expand at the highest CAGR from 2019 to 2027.

    Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60162

    High Prevalence of Urinary Incontinence and Overactive Bladder to Propel Market

    Urinary incontinence is one of the highly prevalent and largely underreported and underdiagnosed urological disorders across the globe. It affects millions of people and has severe impact on physical, psychological, as well as emotional health. Twice as many women as men are affected by this condition and its incidence increases with age. Several factors such as weak pelvic floor muscles, urethral sphincters, obesity, pregnancy & childbirth, urinary tract infection, and neurological disorders cause urinary incontinence. An estimated 200 million people globally are affected by some form of urinary incontinence or bladder problems. Stress urinary incontinence is the most common form affecting millions of people. Various studies have suggested that 24% to 45% of women aged above 30 suffer from stress urinary incontinence. Large patient pool with stress urinary incontinence and overactive bladder symptoms is projected to fuel the growth of the global urinary incontinence treatment devices during the forecast period.

    Download Brochure Copy of this Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60162

    Electrical Stimulation Devices to be Most Attractive Segment

    The report offers detailed segmentation of the global urinary incontinence treatment devices market based on product, incontinence type, and end-user. In terms of product, the electrical stimulation devices segment is poised to account for leading share of the global market during the forecast period. Factors attributed to the higher share of the segment include rise in demand for minimally invasive/wearable and non-implantable electrical stimulation devices to strengthen the pelvic floor muscles, high success rates with electrical stimulation devices, and favorable medical reimbursement policies in developed countries for implantable electrical stimulation devices. Development and launch of new electrical stimulation devices for percutaneous tibial nerve stimulation for the treatment of overactive bladder (such as Medtronic plc’s NURO System) is projected to drive the segment during the forecast period. Moreover, recent launch of wearable electrical stimulation device, INNOVO, by Atlantic Therapeutics and rise in demand for InControl Medical’s FDA-approved over-the-counter electrical stimulation device are expected to propel the segment during the forecast period.

    Urge Urinary Incontinence Segment to Dominate Market

    In terms of incontinence type, the urge urinary incontinence segment is projected to dominate the global urinary incontinence treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Millions of people across the globe are affected by overactive bladder which leads to urge urinary incontinence. Dominance of the segment is attributed to higher cost of treatment devices, especially implantable electrical stimulation devices, than other treatment devices/methods. Therefore, increase in incidence of urge urinary incontinence, rise in adoption of electrical stimulation devices for overactive bladder treatment, and new product launches are expected to contribute to the growth of the segment during the forecast period.

    Hospitals Segment to Lead Market

    Based on end-user, the hospitals segment is projected to account for major share of the global urinary incontinence treatment devices market from 2019 to 2027. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Ambulatory surgery centers is expected to be the second leading segment in terms of market share during the forecast period. High share of the segment is attributed to increase in the number of surgical procedures for the treatment of all types of urinary incontinence and favorable reimbursement policies for medical devices in most of the developed and developing countries. The home use segment is likely to grow at a rapid pace from 2019 to 2027. Availability and high adoption of over-the-counter electrical stimulation and non-invasive treatment devices for the effective management of urinary incontinence are the key factors driving the home use segment.

    Europe to Create High Incremental Opportunity

    In terms of revenue, North America is projected to dominate the global urinary incontinence treatment devices market from 2019 to 2027. This is attributed to early adoption of technologies, large patient pool of urinary incontinence, and easy availability & lucrative medical reimbursement policies in the U.S. and Canada. Europe is anticipated to be the second largest and most attractive market for urinary incontinence treatment devices. The market in the region is expected to expand at a high CAGR during the forecast period due to high prevalence and increase in incidence of urinary incontinence, surge in adoption of technologically advanced products, large base of medical devices companies, and large number of products in the pipeline for the treatment of urinary incontinence. The market in the U.K. is likely to expand at the highest CAGR during the forecast period. The country is projected to gain market share from 2019 to 2027. An estimated 15,000 mid-urethral sling surgical procedures (MUS) in women are performed in the U.K. each year. Moreover, high incidence of post radical prostatectomy urinary incontinence in men is anticipated to accelerate the growth of the market in the country during the forecast period. Asia Pacific is expected to be the second fastest growing market for urinary incontinence treatment devices owing to large population in countries such as India and China, large geriatric population in Japan, and improving health care facilities.

    New Product Development and Launch in International Market: Key Trend among Leading Players

    The report also provides profiles of leading players operating in the global urinary incontinence treatment devices market. Boston Scientific Corporation, C. R. Bard, Inc. (Becton, Dickinson and Company), Coloplast Group, Promedon Group, Medtronic plc, and Ethicon US, LLC. (Johnson & Johnson) are the major players operating in the market offering products with proprietary technologies. Several companies have introduced mini slings for minimally invasive placement of mid-urethral slings with polypropylene sling material. In March 2016, Medtronic plc launched the NURO System, a percutaneous tibial neuromodulation device for the treatment of overactive bladder. The NURO System is the second product in the market after Cogentix Medical’s Urgent PC that targets tibial nerve for pelvic floor strengthening. Other prominent players in the global urinary incontinence treatment devices market include ZSI Surgical Implants S.R.L., InControl Medical LLC, Hollister Incorporated, Atlantic Therapeutics Group Ltd., B. Braun Melsungen AG, A.M.I. GmbH, and Teleflex Incorporated


  • Chromoendoscopy Agents Market is Projected to Report a CAGR of 3.4% From 2018 to 2026

    Chromoendoscopy Agents Market – Snapshot

    Chromoendoscopy is an adjunctive endoscopy technique that involves spraying of dyes on the gastrointestinal mucosal surface to identify specific epithelia or to enhance mucosal surface characteristics of the gastrointestinal epithelium. It is performed to aid in the detection of subtle lesions or to allow directed targeting of biopsies to increase the yield of endoscopic diagnostic accuracy.

    The global chromoendoscopy agents market was valued at US$ 108.9 Mn in 2017 and is anticipated to reach US$ 146.5 Mn by 2026, expanding at a CAGR of 3.4% from 2018 to 2026. Rise in prevalence of gastrointestinal diseases, technological advancements in imaging techniques, surge in awareness among people about preventive measures of cancer, and increase in the number of endoscopy procedures are factors projected to propel the global market during the forecast period.

    The global population is ageing rapidly. According to the WHO, nearly 2 billion people are expected to be aged 60 and above by 2050, which is around 16.7% of the global population. The population in developed countries such as those in Western Europe, Japan, and the U.S. is ageing at a high rate. Some reasons behind it are better health care infrastructure & polices and adoption of advanced medical techniques. Additionally, access to various diagnostic and treatment services has improved in these countries in the past few years. This, in turn, has increased the life expectancy of the overall population. Treatment procedures such as colonoscopy, lung surgeries, hip & knee implants, gastrointestinal endoscopic procedures, and bariatric surgeries are common among the geriatric population. A rise in the geriatric population leads to high rates of ailments. These factors are likely to drive demand for and adoption of endoscopic devices and agents.

    Download Brochure Copy of Chromoendoscopy Agents Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37196

    The global chromoendoscopy agents market has been segmented based on product type, application, end-user, and region. In terms of product type, the absorptive agents segment is projected to account for major share of the market. Absorptive agents improve the recognition of minute changes in the surface pattern by enhancing the contrast of raised and deepened area. This facilitates the visualization and detection of dysplastic and malignant lesions in the gastrointestinal tract. Based on application, the colorectal cancer segment held major share of the market in 2017. The segment is anticipated to expand at a higher CAGR than the other segments during the forecast period. Chromoendoscopy agents have proven to be effective in the detection and visualization of colon neoplasia.

    Read Press Release of Chromoendoscopy Agents Market: https://www.transparencymarketresearch.com/pressrelease/chromoendoscopy-agents-market.htm

    In terms of region, the global chromoendoscopy agents market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2017. Large patient population and presence of major medical devices companies in these regions can be attributed to high share of these regions. Moreover, rise in prevalence of gastrointestinal diseases and increase in the geriatric population drive the chromoendoscopy agents market in these regions. The market in Asia Pacific is projected to expand at a high CAGR owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the chromoendoscopy agents market in Asia Pacific in 2017. The market in India is anticipated to expand at a significant CAGR during the forecast period. Furthermore, increase in investment by leading market players and health care providers is expected to fuel the growth of the market in the region. These factors are likely to drive demand for chromoendoscopy agents in the near future. The market in Latin America and Middle East & Africa is projected to expand at a steady pace during the forecast period.

    Prominent players operating in the global chromoendoscopy agents market include Cosmo Pharmaceuticals NV, Provepharm Life Solutions, Enzo Life Sciences, Inc., Sisco Research Laboratories Pvt. Ltd., HISTALIM, Merck KGaA, Thermo Fisher Scientific, Inc., and LobaChemie Pvt. Ltd.


  • Vascular Grafts Market to Expand at a Healthy CAGR of 5.0% From 2018 to 2026

    Global Vascular Grafts Market – Snapshot 

    Vascular grafts are used to redirect blood flow from one part of the body to another by connecting blood vessels. Vascular grafting surgery is performed to treat ischemia caused by atherosclerosis, organ transplantation, or for vascular access in hemodialysis. However, demand for vascular grafts is anticipated to decline during the forecast period owing to increase in adverse effects like decellularized xenogeneic grafts increase the rate of infection, thrombosis, and aneurysms.

    The global vascular grafts market was valued at US$ 2,010.1 Mn in 2017 and is projected to expand at a CAGR of 5.0% from 2018 to 2026 to reach US$ 3,000 Mn by 2026. High incidence rate of cardiovascular diseases, peripheral diseases, and rise in geriatric population are likely to fuel the growth of the global market from 2018 to 2026. Surge in government investment in health care infrastructure and strategic alliances among players to penetrate the emerging markets are expected to propel the global market during the forecast period.

    In terms of product, the global vascular grafts market has been segmented into endovascular stent grafts, peripheral vascular grafts, hemodialysis access grafts, bypass grafts, and others. The endovascular stent grafts segment held the largest market share in 2017. Moreover, the segment is anticipated to expand at a high CAGR during the forecast period due to high demand for minimally invasive surgeries and rise in preference for stent grafts to treat atherosclerosis. Based on source, the global market has been classified into synthetic, biological, and biosynthetic.

    Download Brochure Copy of Vascular Grafts Market https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=62916

    The synthetic segment is projected to dominate the global market during the forecast period owing to its good materialistic properties such as flexibility. In terms of size of vascular graft, the global vascular graft market has been bifurcated into large and small. The small segment is expected to expand at a high CAGR due to increase in focus of major players on the development of small size vascular grafts to treat narrow vascular atherosclerosis. Based on end-user, the global market has been divided into hospitals, ambulatory surgery centers, cardiac catheterization laboratories, specialty clinics, and others. The hospitals segment accounted for the largest market share in 2017. The segment is expected to expand at a significant CAGR during the forecast period.

    North America is projected to account for major share of the global vascular grafts market from 2018 to 2026, supported by rise in prevalence of cardiovascular diseases and increase in the number of vascular surgeries. According to the Journal of Vascular Surgery (2012), critical limb ischemia is associated with significant cost to the U.S. health care system and is estimated to exceed US$ 3 Bn annually. According to data provided by the American College of Cardiology, more than 130 million adults in the U.S. are anticipated to have some form of cardiovascular diseases (CVD) by 2035, and the total cost of CVD is expected to reach US$ 1.1 Trn in 2035. The vascular graft market in Asia Pacific is likely to expand at a high CAGR during the forecast period due to increase in focus on development of health care infrastructure by both public and private hospitals and high cardiovascular patient pool in countries such as India and China.

    Read Press Release of Vascular Grafts Market : https://www.transparencymarketresearch.com/pressrelease/vascular-grafts-market.htm

    Key companies operating in the global vascular grafts market and profiled in the report include W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG (Getinge Group), BD, LeMaitre Vascular, Inc., B. Braun Melsungen AG, Cook Medical, Medtronic plc, Artegraft, Inc., Vascutek Ltd., Vascular Graft Solution Ltd., Heat Medical Europe BV, and CryoLife, Inc.


  • Cardiac Arrest Treatment Market will Likely to Expand at a Steady CAGR of 4.4% from 2019 to 2027

    Cardiac Arrest Treatment Market – Snapshot

    Cardiac arrest is defined as a sudden and abrupt loss of heart function, consciousness, and apnea or agonal breathing. It is a heterogeneous condition in terms of underlying pathology. It results from an electrical disturbance in the heart because of a problem with electrical signals. The disturbance leads to disruption in pumping action and stoppage of blood flow to the body. Cardiac arrest is often fatal. If appropriate steps are not taken immediately, sudden cardiac arrest can lead to death. The most common cause of a cardiac arrest is abnormal heart rhythm such as ventricular tachycardia or ventricular fibrillation. Other causes of cardiac arrest include thickened heart muscles (cardiomyopathy), heart medications, electrical abnormalities, blood vessel abnormalities, recreational drug use, and scarring of the heart tissue.

    Obesity, diabetes mellitus, smoking, high cholesterol, high blood pressure, and sedentary lifestyles are the primary causes of heart failure and cardiac arrest. Rise in the number of people afflicted by these diseases is projected to drive demand for cardiac arrest treatment. According to the American Heart Association’s 2017 Heart Diseases and Stroke Statistics update, the number of people diagnosed with heart failure is increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with heart failure. There are 22 million people living with congestive heart failure across the world and additional 2 million people are diagnosed every year. According to the American Heart Association, congestive heart failure is one of the leading causes of death in the U.S., accounting for 8.5% of the total population. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths occur due to sudden cardiac arrest across the globe each year. Sudden cardiac death accounts for about 20% of all mortalities in the West. According to the U.S.

    Download Brochure Copy of Cardiac Arrest Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61416

    National Library of Medicine of the National Institutes of Health, 40% to 50% of all cardiovascular deaths are sudden cardiac deaths (SCDs) and nearly 80% of these are caused by ventricular tachyarrhythmia. Therefore, about 6 million sudden cardiac deaths occur each year due to ventricular tachyarrhythmia. The overall prevalence of first degree atrioventricular block among the adult population in the U.S. is 3.7%. Prevalence of atrioventricular block is higher in patients with coronary heart diseases. Dual CRT pacemakers are implanted due to symptomatic bradycardia, which is caused by sick sinus syndrome or atrioventricular block or both. Untreated atrioventricular block will not only lead to heart failure, but also sudden cardiac death. However, stringent regulations for medical devices required for the treatment of cardiac arrest are expected to restrain the market during the forecast period.

    The global cardiac arrest treatment market has been segmented based on treatment, sales channel, and region. In terms of treatment, the medical devices segment held major market share in 2018 and the trend is projected to continue during the forecast period. The beta blockers sub-segment is anticipated to dominate the drugs segment from 2019 to 2027. In terms of sales channel, the hospitals segment is likely to lead the global cardiac arrest treatment market during the forecast period.

    Read Press Release of Cardiac Arrest Treatment Market : https://www.transparencymarketresearch.com/pressrelease/cardiac-arrest-therapeutics-market.htm

    Geographically, North America dominated the global cardiac arrest treatment market in 2018, accounting for the largest share. The region was the largest market for cardiac arrest treatment due to high adoption rate of CRT for cardiac arrest treatment among cardiologists and heart specialists and presence of large number of AED centers. Moreover, increase in incidence of cardiovascular disorders and advancements in medical devices for the treatment of cardiac arrest drive the cardiac arrest treatment market in North America. The market in Asia Pacific is expected to expand at a high CAGR from 2019 to 2027. Asia Pacific comprises major economies such as China, Japan, India, Australia, South Korea, and New Zealand. The cardiac arrest treatment market in Asia Pacific is growing rapidly compared to Europe and North America, which have shown stagnant growth in the past few years. Factors contributing to strong market growth in Asia Pacific are increase in incidence of sudden cardiac arrest (SCA), large patient base, rise in purchase of AEDs for organizational and corporate defibrillation programs, over-the-counter availability of AEDs, increase in disposable income, and subsequent spending on health care.

    Key players operating in the global cardiac arrest treatment market include Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.


  • Red Biotechnology Market is Projected to Expand at a CAGR of 6% From 2019 to 2027

    Red Biotechnology Market: Competitors’ Concentration on Cancer Therapeutics Research to Underpin Growth

    Ever since the era of biotechnology began, with the development of recombinant DNA (rDNA) techniques, countless experiments and research regarding the implication of biotechnology to boost health continue to spawn. The advancement of biotechnology has opened new doors to designing novel therapeutic drugs for sophisticatedly fighting diseases.

    Rapid advancements in stem cell research emphasize using a patient’s own cells to design highly personalized therapeutic alternatives. Similarly, genetic engineering technology encompasses editing the genetic composition of patients to encounter specific points of interest. Several measures are being taken to explore and incorporate biotechnology into the creation of personalized medical care. The application of biotechnology towards personalized medical treatments is likely to open several opportunities for red biotechnology market competitors. Although red biotechnology sustains on an upward growth trajectory in wake of its consist contribution in bettering healthcare, it is imperiled to potential setbacks that cannot be denied. The influence of regional governance on the pricing of medication brings along an undermining aspect, as growing innovations need to be remunerated.

    The new study by TMR reveals key insights into the red biotechnology landscape, allowing report audiences to gain a holistic market overview. According to this TMR study, sales revenues from the red biotechnology market valued at US$ 314.2 billion in 2018. The increasing prevalence of chronic diseases, rapid expansion of the biopharmaceutical industry, and increased global expenditure on the healthcare industry are likely to uphold the growth of the red biotechnology market. Moreover, the growing awareness of chronic disease treatment and robust pipeline of new therapeutic molecules are expected to drive the global red biotechnology market.

    Download Brochure Copy of Red Biotechnology Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2063

    Notable Trends Shaping the Future of the Red Biotechnology Market

    AI Ushers in the New Era of Biotechnology Research

    The transforming utilization of artificial intelligence across a wide array of applications has not been unnoticed. Ahead of this, its use has gradually commenced revolutionizing research activities in the field of biotechnology, as it dramatically minimizes the cost and time involved in the development of life-saving drugs. Companies within the biotechnology space have gained a competitive edge with the implications of cloud-based technology and AI, and increased focus on R&D.

    Significant Investments in the Healthcare Space

    There is a continuously growing buoyancy for supporting industries in the biotech sector, including health service companies. Healthcare start-ups are shining brightly for investors, particularly in areas such as biotechnology. The healthcare industry, as a whole, has cited that dollars of investments and higher valuations are likely to stay consistent over the foreseeable future, giving an edge to research activities for biopharmaceutical production.

    Strategic Collaborations Lay the Grounds for Success

    Red biotechnology market players are relying on strategic mergers and acquisitions to strengthen their position in the market. As enhanced therapeutics play a major role in global disease mitigation, red biotechnology market players are emphasizing on strategic collaborations to enhance their level of expertise while bringing in innovative products. With collaboration agreements, red biotechnology market players are likely to gain major support for biopharmaceutical production, which is picking pace rapidly.

    Read Press Release of Red Biotechnology Market: https://www.transparencymarketresearch.com/pressrelease/red-biotechnology-market.htm

    Growing Demand for Therapeutics to Stir New Possibilities

    The growing rate of chronic diseases is compelling researchers to develop advanced drugs and therapeutics that are capable of battling chronic and progressive diseases. On account of continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are gaining significant traction, thereby boosting developments in the red biotechnology market.

    Key Success Strategies for Red Biotechnology Competitors

    Strengthen Partnership and Distribution Agreements in Developing Countries

    Global red biotechnology market players are emphasizing on developing countries, particularly in the Asia Pacific region. With major initiatives taken in response to the growing drug and biologics demand, and growing patient population in this region, global market players concentrate on strengthening distribution and partnership agreements in developing countries to leverage major demand for biopharmaceuticals and biosimilars.

    Looking for exclusive market insights from business experts? Request a Custom Report of Red Biotechnology Market

    Expand Global Oncology Portfolio

    Growing incidences of cancer across the globe have spawn major developments in cancer therapeutics, resulting in increasing investments in cancer research and drug development. Red biotechnology market competitors have recognized the importance of cancer therapeutics, directing major focus towards oncology portfolio expansion.

    Greater Investment in R&D to Develop Novel Biopharmaceuticals

    Biopharmaceuticals production continues to be the most sought-after application of red biotechnology on account of the fast-growing demand for these drugs that target disease pathways, and provide superior efficacy and safety. Their ability to treat previously untreatable diseases have made biologics widely accepted among end users, driving the demand for hefty investment in biopharmaceutical R&D.

    Boost Market Presence in the U.S.

    There is a major concentration of entrepreneurialism and research in U.S. biotechnology companies, with a biotechnology cluster based in the country. Higher rate of acceptance of new biopharmaceutical drugs, coupled with massive product launches in North America, is attributed to the dominance of the region, wherein, the U.S. is likely to thrive as a leader in the biotechnology space. A large number of mature biotechnology companies and pharmaceutical manufacturers located in the U.S. are attracting red biotechnology market contributors in a bid to expand their presence in the country.

    Innovative Product Development and Clinical Trials

    Companies operating in the red biotechnology market continue to engage in the development of innovative products and invest in associated clinical trials to gain regulatory backing. As R&D efforts for producing advanced disease therapeutics continues to flourish, red biotechnology innovations remain a vital profit-gaining strategy for competitors.

    Competitive Assessment

    Leading players in global red biotechnology market, including

    • F. Hoffmann-La Roche
    • Amgen Inc.
    • Gilead Sciences Inc.
    • CSL
    • Pfizer Inc.

    accounted for nearly half of the market share in 2018. Expansion strategies such as business acquisitions remain a vital tactic adopted by competitors in the red biotechnology market. Companies are entering into strategic collaborations with other biotechnology firms located in lucrative geographies, in a bid to expand their consumer base. Apart from this, innovative product launches allow red biotechnology market players to strengthen their market position, with focus centered on greater R&D activities. Considering the global inclination towards biosimilars that meet the consumer requirements for both, efficacy and cost-effectiveness, notable developments related to biosimilars remain a focal point for competitors.


connect